Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
作者： L M Minasian , R J Motzer , L Gluck , M Mazumdar , V Vlamis
DOI: 10.1200/JCO.1993.11.7.1368
关键词: Toxicity 、 Gastroenterology 、 Surgery 、 Interferon alfa 、 Alpha interferon 、 Internal medicine 、 Medicine 、 Renal cell carcinoma 、 Vinblastine 、 Clear cell carcinoma 、 Immunotherapy 、 Interferon
摘要: PURPOSE Three trials were conducted to define the efficacy and toxicity of interferon alfa-2a in the treatment of metastatic renal cell cancer. Univariate and multivariate analyses were …
sci-hub.se 参考文章(35)
Eric R. Sargent, Leonard G. Gomella, Arie Belldegrun, W. Marston Linehan, Attan Kasid, Epidermal Growth Factor Receptor Gene Expression in Normal Human Kidney and Renal Cell Carcinoma Journal of Urology. ,vol. 142, pp. 1364- 1368 ,(1989) , 10.1016/S0022-5347(17)39100-0
Avishay Sella, Christopher J. Logothetis, Karen Fitz, Francisco H. Dexeus, Robert Amato, Robert Kilbourn, Sidney Wallace, Phase II Study of Interferon-α and Chemotherapy (5-Fluorouracil and Mitomycin C) in Metastatic Renal Cell Cancer The Journal of Urology. ,vol. 147, pp. 573- 577 ,(1992) , 10.1016/S0022-5347(17)37309-3
Donald L. Trump, Robert S. Witte, Paul J. Elson, Prognostic Factors for Survival in Patients with Recurrent or Metastatic Renal Cell Carcinoma Cancer Research. ,vol. 48, pp. 7310- 7313 ,(1988)
J A Neidhart, S A Anderson, J E Harris, J J Rinehart, J Laszlo, F H Dexeus, L H Einhorn, D L Trump, P W Benedetto, R L Tuttle, Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. Journal of Clinical Oncology. ,vol. 9, pp. 832- 836 ,(1991) , 10.1200/JCO.1991.9.5.832
David M. Nanus, Victor Reuter, Dean F. Bajorin, Paul O'Moore, Carl Louison, Jacqueline Iversen, Anthony P. Albino, Robert J. Motzer, William P. Tong, George J. Bosl, Howard I. Scher, Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression Cancer Research. ,vol. 52, pp. 5775- 5779 ,(1992)
N. H. Bander, G. Gastl, D. M. Nanus, L. M. Pfeffer, C. L. Finstad, A. P. Albino, Anti-Proliferative and Anti-Tumor Effect of α-Interferon in Renal Cell Carcinoma: Correlation with the Expression of a Kidney Associated Differentiation Glycoprotein Basic and Clinical Research on Renal Cell Carcinoma. ,vol. 50, pp. 115- 120 ,(1992) , 10.1007/978-3-642-76863-7_11
S Ferrone, P Giacomini, P B Fisher, S Pestka, A Aguzzi, Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. Journal of Immunology. ,vol. 133, pp. 1649- 1655 ,(1984)
Michael A Caligiuri, Christine Murray, Robert J Soiffer, Thomas R Klumpp, Michael Seiden, Keith Cochran, Christine Cameron, Christopher Ish, Lynn Buchanan, Denise Perillo, None, Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. Journal of Clinical Oncology. ,vol. 9, pp. 2110- 2119 ,(1991) , 10.1200/JCO.1991.9.12.2110
J R Quesada, A Rios, D Swanson, P Trown, J U Gutterman, Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. Journal of Clinical Oncology. ,vol. 3, pp. 1522- 1528 ,(1985) , 10.1200/JCO.1985.3.11.1522
R A Figlin, A Belldegrun, N Moldawer, J Zeffren, J deKernion, Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. Journal of Clinical Oncology. ,vol. 10, pp. 414- 421 ,(1992) , 10.1200/JCO.1992.10.3.414